Shire PLC (SHPG) Position Trimmed by TNB Financial
TNB Financial decreased its position in shares of Shire PLC (NASDAQ:SHPG) by 21.9% during the 4th quarter, Holdings Channel reports. The fund owned 16,959 shares of the biopharmaceutical company’s stock after selling 4,755 shares during the quarter. TNB Financial’s holdings in Shire were worth $2,631,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. SeaCrest Wealth Management LLC bought a new position in Shire during the 4th quarter worth approximately $107,000. BB&T Investment Services Inc. boosted its stake in Shire by 1,672.3% during the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 786 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new position in Shire during the 3rd quarter worth approximately $159,000. Benjamin F. Edwards & Company Inc. boosted its stake in Shire by 277.4% during the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 1,253 shares of the biopharmaceutical company’s stock worth $194,000 after acquiring an additional 921 shares during the last quarter. Finally, New England Research & Management Inc. bought a new position in Shire during the 3rd quarter worth approximately $230,000. 20.31% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have weighed in on the stock. Cowen set a $225.00 price target on shares of Shire and gave the company a “buy” rating in a research note on Friday, January 5th. Royal Bank of Canada set a $192.00 price target on shares of Shire and gave the company a “buy” rating in a research note on Monday. BidaskClub lowered shares of Shire from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Shire in a research note on Wednesday, January 3rd. Finally, Cantor Fitzgerald set a $222.00 price target on shares of Shire and gave the company a “buy” rating in a research note on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the stock. Shire presently has a consensus rating of “Hold” and an average price target of $212.50.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.watchlistnews.com/shire-plc-shpg-position-trimmed-by-tnb-financial/1850430.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.